- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schering acquires Japanese rights to MS-325
An agreement reached Jan. 10 gives Schering exclusive rights to codevelop, manufacture, and market Epix Medical's premier vascular agent in Japan. The product, MS-325, is in phase III clinical trials to document its ability to help visualize peripheral
An agreement reached Jan. 10 gives Schering exclusive rights to codevelop, manufacture, and market Epix Medical's premier vascular agent in Japan. The product, MS-325, is in phase III clinical trials to document its ability to help visualize peripheral vascular disease with MRI.
Schering gained worldwide sales and marketing rights to the product, excluding Japan, in June. The terms of the latest deal call for Schering to pay Epix $3 million up front, along with additional milestone payments. Simultaneously with this transaction, Epix reacquired rights to the Japanese market for MS-325 from Daiichi Radioisotope Laboratories. Under terms of that agreement, Epix will pay Daiichi $2.8 million in up-front fees and additional milestone payments. Daiichi will also receive a royalty from Epix on net sales of MS-325 in Japan.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
